BlueWillow Biologics Announces Issuance of Therapeutic Cancer Vaccine Patent
Retrieved on:
Wednesday, May 30, 2018
ANN ARBOR, Mich., May 30, 2018 /PRNewswire/ -- BlueWillow Biologics today announced the issuance of U.S. patent number 9,974,844 entitled "Cancer Vaccine Compositions And Methods Of Using The Same," to the University of Michigan under exclusive license to BlueWillow.
Key Points:
- ANN ARBOR, Mich., May 30, 2018 /PRNewswire/ -- BlueWillow Biologics today announced the issuance of U.S. patent number 9,974,844 entitled "Cancer Vaccine Compositions And Methods Of Using The Same," to the University of Michigan under exclusive license to BlueWillow.
- "The awarding of this patent demonstrates that our NanoVax technology has potential in areas beyond infectious disease.
- BlueWillow Biologics is a privately-held biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing and commercializing vaccines using its patented NanoVax technology platform.
- BlueWillow is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.